Your browser doesn't support javascript.
loading
MicroRNA-146a as a Prognostic Biomarker for Esophageal Squamous Cell Carcinoma.
Sadegh Shesh Poli, Maryam; Khajeniazi, Safoura; Behnampour, Nasser; Kalani, Mohammad Reza; Moradi, Abdolvahab; Marjani, Abdoljalal.
Afiliação
  • Sadegh Shesh Poli M; School of New Technologies, Golestan University of Medical Sciences, Gorgan, Iran.
  • Khajeniazi S; Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
  • Behnampour N; Health Management and Social Development Research Center, Gorgan, Iran.
  • Kalani MR; Molecular Medicine Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
  • Moradi A; Gastroenterology and Hepatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
  • Marjani A; Abdoljalal Marjani Metabolic Disorders Research Center, Department of Biochemistry and Biophysics, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
Cancer Manag Res ; 12: 973-980, 2020.
Article em En | MEDLINE | ID: mdl-32104079
ABSTRACT
BACKGROUND AND

AIMS:

MicroRNAs including miR146a have a regulatory role on the expression of genes and act with binding to 3'-UTR region of the genes. Cyclooxygenase-2 (COX-2) is involved in carcinogenesis as an inflammatory marker, and microRNA-146a (miR-146a) as a negative regulatory factor. We aimed to evaluate miR146a expression as a prognostic or diagnostic biomarker for esophageal squamous cell carcinoma (ESCC) and also an association between miR146a and COX2 expression. MATERIALS AND

METHODS:

We quantified the level of miR-146a and COX-2 expression in cancerous and adjacent normal tissue samples obtained from 34 patients with ESCC, using real-time-PCR. Statistical analyses were conducted using one-sample t-test. Receiver-operating characteristic (ROC) curve and Kaplan-Meier analysis were applied to assay miR146a as a diagnostic and prognostic marker, respectively, during 4 years of the study. Furthermore, the Cox regression model was performed to assay the hazard ratio (HR). The association between miR-146a and COX2 expression level in ESCC patients was evaluated by nonparametric Spearman's rho analysis.

RESULTS:

The results revealed a reduction of miR-146a expression in 50% of cancerous tissue when compared with adjacent normal regions (P-value=0.127). COX-2 expression in 80% of ESCC patients was higher than in the controls (P-value=0.001). Overall, in 60% of cases, direct association was seen between microRNA-146a and COX-2 expression level (correlation coefficient= 0.438, P-value=0.011). COX2 can be considered as a diagnostic biomarker (AUC=0.834, sensitivity=72%, specificity =83%, P-value<0.0001) but miR146a cannot be considered as a diagnostic biomarker (AUC=0.553, sensitivity=88%, specificity =28%, P-value=0.453). Survival analysis by Kaplan-Meier method showed miR146a and COX2 expression can be probably considered as prognostic biomarkers for ESCC because patients with high expression of miR146a had 7 months shorter life span and patients with low expression of COX2 had 8 months shorter life span.

CONCLUSION:

COX2 expression is a diagnostic biomarker. MiR-146a and COX2 expression can probably be considered as prognostic biomarkers for survival in ESCC.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article